Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China NT Pharma Group Company Limited (1011.HK)
Suzhou, CN
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.45% | -6.67% | -13.85% | -26.32% | -31.71% | -31.71% | +25.84% | +1,020.00% | -56.92% | -99.73% | -49.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-36.4%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+78.9% ★ Q4'25: +98.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-137.9% Q4'25: -45.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-51.2% Q4'25: -100.9% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-34.7% Q4'25: -137.6% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+133.6% Q4'25: +241.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-25.73× Q4'25: -6.48× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
|---|---|---|---|---|---|---|
| Revenue |
2.76B
est: 2.49B (+10.8%)
|
739.13M
est: 1.13B (-34.9%)
|
847.73M
est: 705.43M (+20.2%)
|
915.12M
est: 838.12M (+9.2%)
|
604.85M
est: 1.31B (-53.7%)
|
571.52M
est: 1.55B (-63.1%)
|
| EBITDA |
389.80M
est: -156.04M (+349.8%)
|
-1.10B
est: -69.74M (-1,473.7%)
|
143.25M
est: -43.36M (+430.4%)
|
86.29M
est: -51.51M (+267.5%)
|
303.57M
est: 88.45M (+243.2%)
|
-210.92M
est: -97.02M (-117.4%)
|
| EBIT |
357.47M
est: -802.39M (+144.6%)
|
-1.13B
est: -358.60M (-213.7%)
|
127.32M
est: -222.94M (+157.1%)
|
63.28M
est: -264.87M (+123.9%)
|
269.15M
est: 46.64M (+477.1%)
|
-481.64M
est: -498.90M (+3.5%)
|
| Net Income |
234.38M
est: 50.66M (+362.6%)
|
-1.11B
est: -19.56M (-5,571.6%)
|
87.69M
est: 13.46M (+551.7%)
|
116.18M
est: 16.81M (+591.3%)
|
165.20M
est: 83.91M (+96.9%)
|
-957.67M
|
| SGA |
581.92M
est: 5.59B (-89.6%)
|
709.12M
est: 2.50B (-71.6%)
|
319.88M
est: 1.55B (-79.4%)
|
311.52M
est: 1.85B (-83.1%)
|
243.69M
est: 138.68M (+75.7%)
|
362.48M
est: 1.83B (-80.2%)
|
| EPS |
0.23
est: 0.19 (+19.9%)
|
-1.03
est: -0.07 (-1,283.9%)
|
0.06
est: 0.05 (+20.9%)
|
0.08
est: 0.06 (+17.3%)
|
0.11
|
-0.61
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ching Mei Ng | Executive Director | 844.8K | female |
| Tit Ng | Co-Founder & Executive Chairman | 844.8K | male |
| Bozhi Zhang | Chief Executive Officer | — | male |
| Jing Fang | Chief Financial Officer | — | female |
| Yifang Li | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1011.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
